March 24, 2023

Expert Point of View: Xin Gao, MD

Dr. Xin Gao from Harvard Medical School shares new insights on sacituzumab govitecan's efficacy in metastatic urothelial cancer patients and examines future research prospects.

The ASCO Post

June 05, 2023

Study Sends Strong Signal Not to Sequence Immune Checkpoint Inhibitors in Advanced Kidney Cancer

Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor treatment in metastatic renal cell carcinoma: primary PFS analysis from the Phase 3, randomized, open-label CONTACT-03 study

Dana-Farber

July 11, 2024

Association of Genetic Risk for Prostate Cancer With Early Prostate Cancer Death

A recent cohort study found that men at a higher genetic risk for prostate cancer were more likely to experience early death from prostate cancer compared to men with a lower genetic risk for the dise...

The ASCO Post

August 15, 2023

Study Shows Immunotherapy May Benefit a Subset of Patients with Penile Cancer

Penile cancer is a rare disease with approximately 2070 new cases each year in the US.

Dana-Farber

February 20, 2023

Nivolumab After Surgical Resection Improves Disease-Free Survival for Patients With High-Risk Muscle-Invasive Urothelial Carcinoma

Adjuvant therapy with the immune checkpoint inhibitor nivolumab following surgery improved disease-free survival in patients with high-risk muscle-invasive urothelial carcinoma, according to new findi...

The ASCO Post

February 20, 2023

Single-Arm Phase II Noninferiority Trial Evaluates Active Surveillance vs Cystectomy Following Neoadjuvant Chemotherapy for Muscle-Invasive Urothelial Carcinoma

Researchers have found that following chemotherapy, 46% of patients with muscle-invasive urothelial carcinoma were able to avoid a cystectomy and achieve a 2-year metastasis-free survival, according t...

The ASCO Post

March 10, 2023

TRITON3 Trial: Rucaparib Extends Progression-Free Survival in Selected Patients With Metastatic Castration-Resistant Prostate Cancer

The poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib prolonged imaging-based progression-free survival vs physician’s choice of therapy in patients with metastatic castration-resistant prostate...

The ASCO Post

February 06, 2025

Results From FIRE-4 Show Liquid Biopsy Can Detect RAS/BRAF-Mutated Metastatic Colorectal Cancer

The results from the phase III FIRE-4 randomized clinical trial showed that liquid biopsy accurately identified patients with RAS/BRAF V600E wild type-mutated metastatic colorectal cancer. These findi...

The ASCO Post

October 06, 2023

Advanced Bladder Cancer Patients Could Keep Their Bladder Under New Treatment Regime, Clinical Trial Shows

In a phase 2 clinical trial that was the first of its kind, doctors found that some patients could be treated with a combination of chemotherapy and immunotherapy without the need to remove their bladder.

Mount Sinai New York